The advancement of antibody discovery technologies like hybridoma, display libraries, Single B-cell sorting/sequencing, and computational modeling has led to the production of thousands of monoclonal antibodies (mAbs). However, identifying the "best-in-class" antibody therapeutics requires rapid assessment using high throughput (HTP) processes.
Recombinant antibodies are monoclonal antibodies produced in vitro through synthetic genes and antibody fragments, instead of using hybridomas. They can take several different formats, such as full-length immunoglobulins (Ig), monovalent antibody fragments such as single-chain fragment variable (scFv) and fragment antigen-binding (Fab), and multimeric diabodies (dimeric scFvs) or triabodies (trimeric scFvs).
A VHH antibody is the antigen binding fragment of heavy chain only antibodies. They are derived from the immune system of camelids such as alpacas. As they are highly stable and much smaller than traditional antibodies, VHH antibodies are ideal for a wide range of applications, including diagnostic tests, therapeutics, and research tools.
High-throughput (HTP) recombinant antibody production is the rapid generation of large numbers of recombinant antibodies. This enables the acceleration of research, paving the way towards clinical trials, as well as streamlining the discovery and development processes.
Biointron’s 2-week high-throughput recombinant antibody production is the leading gene-to-antibody workflow in the industry. We offer the flexibility to rapidly express large amounts of antibodies at varying scales using HEK293 or CHO cells, which are known for efficient recombinant protein production.
Antibody specificity refers to an antibody's ability to selectively bind to a unique epitope on a target antigen while avoiding interactions with unrelated antigens. This property arises from the highly specialized antigen-binding site located in the variable region of the antibody, which determines its unique binding characteristics.
Antibody affinity refers to the strength of the binding interaction between a single antigen epitope and the paratope (binding site) of an antibody. This interaction is a fundamental measure of how well an antibody recognizes its specific antigen target.
Recombinant antibodies are produced using genetic engineering techniques, unlike traditional antibody production, where the immune system generates antibodies without direct control over their sequence. By introducing genes encoding antibody fragments into host cells, such as bacteria or mammalian cells, recombinant antibodies can be expressed, purified, and deployed for applications including research, diagnostics, and therapeutics.
Recombinant antibody expression is a biotechnological process that involves engineering and producing antibodies outside their natural context using recombinant DNA technology.
ScientistとScience Exchangeとのご利用可能です。
